Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2006

View Archived Issues

MPC-7869 studied for drug interaction potential, efficacy in Alzheimer's disease

MK-677 does not affect Alzheimer's disease progression

Sipuleucel-T improves survival in hormone refractory prostate cancer

Acenta and PsychoGenics form psychiatric and neurological disorders collaboration

Alnylam and Inex advance collaboration on systemic delivery of RNAi therapeutics

Alnylam and UT Southwestern to develop RNAi therapeutics for high cholesterol

Transition Therapeutics and Novo Nordisk amend I.N.T. license agreement

Rivastigmine transdermal patch compares well with capsules

Tigris licenses anticancer compound from NIH

Astellas discontinues development of FK-962 for Alzheimer's disease

Cangene's NDA for rhGH Accretropin accepted for review

AstraZeneca files NDA for Seroquel SR

Topical antiinfective REP-8839 begins phase I testing

Starpharma cleared to study SPL-7013 gel for genital herpes prevention

Roche exercises option to Ipsen's antidiabetic drug BIM-51077

U.K. clearance for phase II study of Reolysin with low-dose radiation

Expanded multiple dose phase I trial of CG-0070 in recurrent bladder cancer

Theravance and Astellas add Japan to telavancin collaboration

Mycophenolate mofetil approved in Malaysia for lupus nephritis

Solvay seeks E.U. approval of Synordia

Frova filed for prevention of menstrual migraine

Calpain inhibitor and antioxidant BN-82270 protects from and helps recover hearing loss

First U.S. clinical data on huperzine A, a Chinese herbal medicine for AD

Promising preclinical data on novel classes of compounds developed at Enkam

Recent patents disclose novel antiinfective agents

Recent ViroChem patent reports novel HIV integrase inhibitors

Recent Novartis and Devgen patents describe new treatments for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...